| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
264,900,000 |
| Market
Cap: |
8.27(B) |
| Last
Volume: |
49,305,461 |
Avg
Vol: |
12,650,496 |
| 52
Week Range: |
$31.23 - $31.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
4,785,085 |
| Total Sell Value |
$0 |
$0 |
$0 |
$86,338,289 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
26 |
| End Date |
2025-02-06 |
2024-11-05 |
2024-05-07 |
2023-05-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(584,397) |
0 |
|
- |
|
| Mitchell Dean J |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(103,000) |
0 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,720) |
0 |
|
- |
|
| Vasconcelles Michael |
EVP R&D & MEDICAL AFFAIRS |
• – – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,327) |
0 |
|
- |
|
| Arbuckle Stuart A |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,381) |
0 |
|
- |
|
| Wallace Richard John |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,000) |
0 |
|
- |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(73,274) |
0 |
|
- |
|
| Lentini Renee |
VP & PRIN ACCTG OFFICER |
• – – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,723) |
0 |
|
- |
|
| Thackray Helen M. |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,074) |
0 |
|
- |
|
| Char Daniel |
SVP & CHIEF LEGAL OFFICER |
• – – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,000) |
0 |
|
- |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,039) |
0 |
|
- |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2024-02-05 |
4 |
AS |
$29.30 |
$134,282 |
D/D |
(4,583) |
73,274 |
|
7% |
|
| Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-02-05 |
4 |
AS |
$29.28 |
$588,733 |
D/D |
(20,107) |
584,397 |
|
7% |
|
| Lentini Renee |
VP & PRIN ACCTG OFFICER |
• – – |
2024-02-05 |
4 |
AS |
$29.30 |
$77,088 |
D/D |
(2,631) |
14,723 |
|
7% |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2024-02-05 |
4 |
AS |
$29.30 |
$352,391 |
D/D |
(12,027) |
21,039 |
|
7% |
|
| Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
• – – |
2024-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,350 |
77,857 |
|
- |
|
| Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,234 |
604,504 |
|
- |
|
| Lentini Renee |
VP & PRIN ACCTG OFFICER |
• – – |
2024-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,435 |
17,354 |
|
- |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2024-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,640 |
33,066 |
|
- |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2024-01-16 |
4 |
AS |
$29.64 |
$5,562,450 |
D/D |
(187,667) |
3,426 |
|
5% |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2024-01-16 |
4 |
OE |
$4.83 |
$961,847 |
D/D |
187,667 |
191,093 |
|
- |
|
| Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
• – – |
2023-12-29 |
4 |
A |
$16.01 |
$9,846 |
D/D |
615 |
3,426 |
|
- |
|
| Thackray Helen M. |
|
– • – |
2023-12-29 |
4 |
A |
$29.65 |
$7,472 |
D/D |
252 |
3,074 |
|
- |
|
| Arbuckle Stuart A |
|
– • – |
2023-12-29 |
4 |
A |
$29.65 |
$13,105 |
D/D |
442 |
5,381 |
|
- |
|
| Vasconcelles Michael |
EVP R&D & MEDICAL AFFAIRS |
• – – |
2023-12-29 |
4 |
A |
$16.01 |
$21,245 |
D/D |
1,327 |
1,327 |
|
- |
|
242 Records found
|
|
Page 1 of 10 |
|
|
